The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Non‐Thermal Plasma as a Unique Delivery System of Short‐Lived Reactive Oxygen and Nitrogen Species for Immunogenic Cell Death in Melanoma Cells
Open accessAbstract
Breakthroughs in cancer immunotherapies have demonstrated considerable success, though not without limitations. Non‐thermal plasma (NTP) for cancer therapy has been emerging as a potential adjuvant treatment via induction of immunogenic cell death (ICD). Cancer cells undergoing ICD stimulate a patient's immune system to mount an anticancer response. While promising, the underlying mechanisms of NTP‐induced ICD must be closely examined. Here, the interaction between non‐thermal plasma and cancerous cells is studied. The short‐lived reactive oxygen and nitrogen species (e.g., hydroxyl radicals, atomic oxygen, nitric oxide) produced by plasma are the main effectors that elicit ICD in melanoma while, surprisingly, persistent species do not. This is demonstrated in vitro using a dielectric barrier discharge plasma system and is validated in a vaccination assay in vivo. Plasma generation of reactive species appears to be dictated by the total energy. Collectively, this work provides fundamental insight into plasma interactions with biological material. Furthermore, it lays the foundation for future development of NTP systems for clinical translation. The addition of plasma systems into the existing arsenal of cancer therapies opens the possibility for new combination strategies for safer and more robust control of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death
Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy
Adkins, I., Fucikova, J., Garg, A. D., Agostinis, P., & Špíšek, R. (2014) · OncoImmunology · doi:10.4161/21624011.2014.968434 · Cited by 200
Martin, S., Dudek-Perić, A. M., Maes, H., Garg, A. D., Gabrysiak, M., Demirsoy, S., Swinnen, J. V., & Agostinis, P. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.12.003 · Cited by 54
Cited by
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Chen, C., Ni, X., Jia, S., Liang, Y., Wu, X., Kong, D., & Ding, D. (2019) · Advanced Materials · doi:10.1002/adma.201904914 · Cited by 503
Sakudo, A., Yagyu, Y., & Onodera, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205216 · Cited by 341
Bradu, C., Kutasi, K., Magureanu, M., Puač, N., & Živković, S. (2020) · Journal of Physics D: Applied Physics · doi:10.1088/1361-6463/ab795a · Cited by 318
ROS from Physical Plasmas: Redox Chemistry for Biomedical Therapy
Privat-Maldonado, A., Schmidt, A., Lin, A., Weltmann, K.-D., Wende, K., Bogaerts, A., & Bekeschus, S. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9062098 · Cited by 304
Self-citationFreund, E., Miebach, L., Stope, M., & Bekeschus, S. (2021) · Oncology Reports · doi:10.3892/or.2021.8022 · Cited by 18
Metadata
- Authors
- Lin, A., Gorbanev, Y., De Backer, J., Van Loenhout, J., Van Boxem, W., Lemière, F., Cos, P., Dewilde, S., Smits, E., & Bogaerts, A.
- Venue
- Advanced Science
- Publisher
- Wiley
- Published
- 2019-01-28
- Volume
- 6
- Issue
- 6
- Pages
- 1802062-1802062
- ISSN
- 2198-3844 (ISSN-L)
- OpenAlex
- W2911708154
- Cited by
- 246
- References
- 9
- FWCI
- 22.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.